Compass Therapeutics, Inc.
CMPX
Rank in Stocks
#17922
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing... Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
Share Price
$0.8369
Last synced: 2026-11-09
Market Cap
$150.72M
Change (1 day)
10.29%
Change (1 year)
-81.92%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Compass Therapeutics, Inc. (CMPX)
Category
Healthcare
Operating Margin for Compass Therapeutics, Inc. (CMPX)
Operating Margin as of November 2026 TTM: 0.00%
According to Compass Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for Compass Therapeutics, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | -6,661.76% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
| 2019 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Compass Therapeutics, Inc.'s operating margin
What was Compass Therapeutics, Inc.'s operating margin in 2025?
In 2025, Compass Therapeutics, Inc.'s operating margin was 0.00%, compared with -6,661.76% in 2024.
How has Compass Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Compass Therapeutics, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2024 (-6,661.76%).
How does Compass Therapeutics, Inc.'s operating margin compare with similar companies?
Compass Therapeutics, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.